Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crohn's Pipeline: Janssen Seeks New Niche For Stelara As Biologics Use Rises

This article was originally published in Scrip

Executive Summary

Doctors who treat Crohn's disease are prescribing biologics more frequently than in the past to quickly reduce inflammation, but they're searching for alternatives to tumor necrosis factor (TNF) inhibitors to cut the side effect risks, and that is where the Johnson & Johnson subsidiary Janssen Biotech Inc. may find its best niche for Stelara (ustekinumab).

Advertisement

Related Content

New Crohn’s Indication Puts Janssen’s Stelara On Equal Ground With Anti-TNFs
Bundled Contracts To Defend Against Biosimilars May Face Payer Skepticism

Topics

Advertisement
UsernamePublicRestriction

Register

SC064783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel